Aim. To assess efficiency and safety of high-dose beklometasone dipropionate in patients with bronchial asthma (BA).
Material and methods. The trial included 14 female and 3 male patients with moderate or severe BA (mean age 43,6 years) in declining exacerbation. The patients inhaled beklometasone dipropionate as a dose-adjusted aerosole with built-up spacer (beklojet) in a daily dose 1000-2000 mcg for 8 weeks. Changes in clinical symptoms, life quality (AQLQ) and bronchial permeability (peak flowmetry, FEV1) were registered. Concentration of H2O2 in expired air condensate was measured spectrophotometrically to evaluate activity of airway inflammation. Oral smears were studied mycologically, hydrocortisone in blood plasma was measured with enzyme immunoassay,
Results. The treatment produced positive trend in clinical symptoms and quality of life. Bronchial permeability improved since the 7th treatment day. H2O2 significantly fell, hydrocortisone levels and fungal flora did not change significantly.
Conclusion. Beklometasone dipropionate in high doses for 8 weeks is effective and safe against BA.